Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease

(1)
TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being jointly developed by Eisai and Biogen.

Related Keywords

Japan ,Tokyo ,John Hardy ,Jeffrey Cummings ,Philip Schelten ,Development Code ,Eisai Co Ltd ,Sysmex Corporation ,Biogen Inc ,International Conference On Alzheimer ,International Conference ,Science Behind ,Colin Masters ,Eisai ,Present ,Latest ,Data ,Pipeline ,Assets ,Area ,Alzheimer ,Disease ,Dementia ,15th ,International ,Conference ,Parkinson ,ஜப்பான் ,டோக்கியோ ,ஜான் ஹார்டி ,ஜெஃப்ரி கம்மிங்ஸ் ,வளர்ச்சி குறியீடு ,ேசை இணை லிமிடெட் ,பயோஜென் இன்க் ,சர்வதேச மாநாடு ஆன் முதுமறதி ,சர்வதேச மாநாடு ,அறிவியல் பின்னால் ,கொலின் முதுநிலை ,ேசை ,ப்ரெஸெஂட் ,சமீபத்தியது ,தகவல்கள் ,குழாய் ,சொத்துக்கள் ,பரப்பளவு ,முதுமறதி ,நோய் ,முதுமை ,சர்வதேச ,மாநாடு ,பார்கின்சன் ,